Xvivo Perfusion AB (publ) (LON:0RKL)

London flag London · Delayed Price · Currency is GBP · Price in SEK
184.69
-1.44 (-0.78%)
Dec 30, 2025, 5:13 PM BST
-61.58%
Market Cap474.66M
Revenue (ttm)64.23M
Net Income (ttm)2.36M
Shares Outn/a
EPS (ttm)0.07
PE Ratio201.07
Forward PE57.38
Dividendn/a
Ex-Dividend Daten/a
Volume10,442
Average Volume3,053
Open186.90
Previous Close186.14
Day's Range184.40 - 187.10
52-Week Range160.80 - 519.00
Beta1.84
RSI56.37
Earnings DateJan 27, 2026

About Xvivo Perfusion AB

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermi... [Read more]

Industry Medical - Equipment & Services
Sector Healthcare
Founded 1998
Employees 190
Stock Exchange London Stock Exchange
Ticker Symbol 0RKL
Full Company Profile

Financial Performance

In 2024, Xvivo Perfusion AB's revenue was 822.42 million, an increase of 37.63% compared to the previous year's 597.54 million. Earnings were 172.18 million, an increase of 87.52%.

Financial numbers in SEK Financial Statements

News

Xvivo Perfusion AB (publ) 2025 Q3 - Results - Earnings Call Presentation

2025-10-23. The following slide deck was published by Xvivo Perfusion AB (publ) in conjunction with their 2025 Q3 earnings call.

2 months ago - Seeking Alpha

Xvivo Perfusion AB (publ) (XVIPY) Q3 2025 Earnings Call Transcript

Xvivo Perfusion AB (publ) (OTCPK:XVIPY) Q3 2025 Earnings Call October 23, 2025 8:00 AM EDTCompany ParticipantsChristoffer Rosenblad - Chief Executive...

2 months ago - Seeking Alpha

Xvivo Perfusion AB (XVIPF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst ...

Xvivo Perfusion AB (XVIPF) Q3 2025 Earnings Call Highlights: Strong Organic Growth Amidst Regulatory Challenges

2 months ago - GuruFocus

Q3 2025 Xvivo Perfusion AB Earnings Call Transcript

Q3 2025 Xvivo Perfusion AB Earnings Call Transcript

2 months ago - GuruFocus

Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing ...

Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities

6 months ago - GuruFocus

Q2 2025 Xvivo Perfusion AB Earnings Call Transcript

Q2 2025 Xvivo Perfusion AB Earnings Call Transcript

6 months ago - GuruFocus